International Pharmaceutical Aerosol Consortium on Regulation & Science
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDPs) by collecting and analyzing data, and conducting joint research and development projects. Representing the OINDP industry since 2000, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.
IPAC-RS Roundtable Webinar Series 2021
Starting in 2020, IPAC-RS has organized a number of roundtables with thought leaders to discuss key regulatory and scientific topics in respiratory products. Continuing that practice, in 2021, IPAC-RS launched a new series focusing on drug-device combination products with digital components, and digital-health opportunities and challenges more broadly.
Recordings from the first webinars are available here.
What is a Digital Biomarker and Why Is It Important?
Beyond Usability/Human Factors for Digital Healthcare
Digital Devices: Manufacturing and Design Considerations
The fourth webinar in the series Business Case for Digital Devices is scheduled for Monday, October 4, 2021 at 10:00 AM - 12:00 PM US ET. Click here for abstracts and registration information.
SAVE THE DATE:
November 22, 2021 10:00 AM - 12:00 PM US ET - Digital Devices: Regulatory Challenges and Considerations.
News and Events
Read the IPAC-RS 2020 Year in Review to lean more about IPAC-RS's achievements and the benefits of membership.
The report highlights the impressive work IPAC-RS accomplished in 2020 and showcases the important role our member companies’ played in responding to the global pandemic.
IPAC-RS engages actively in reviewing and commenting on regulatory developments around the world, and works collaboratively with all stakeholders to improve science-based regulations affecting orally inhaled and intranasal pharmaceutical products. IPAC-RS has prepared a summary of relevant global regulatory developments in 2020.
IPAC-RS Regulatory Roundtable Webinar Series
IPAC-RS hosted a Roundtable: A Conversation with the FDA: Perspectives in the Time of COVID-19 on November 2, 2020.
Click here to review the summary of the webinar.